Equities analysts expect INmune Bio Inc (NASDAQ:INMB) to post earnings per share of ($0.20) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for INmune Bio’s earnings, with estimates ranging from ($0.21) to ($0.18). The company is scheduled to report its next quarterly earnings results on Monday, November 11th.

On average, analysts expect that INmune Bio will report full year earnings of ($0.65) per share for the current year, with EPS estimates ranging from ($0.68) to ($0.61). For the next financial year, analysts expect that the company will post earnings of ($0.87) per share, with EPS estimates ranging from ($0.99) to ($0.75). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow INmune Bio.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.16.

A number of research analysts have weighed in on the stock. Maxim Group reaffirmed a “buy” rating and set a $13.00 price target on shares of INmune Bio in a research report on Wednesday, August 14th. HC Wainwright started coverage on shares of INmune Bio in a research note on Wednesday, August 21st. They set a “buy” rating and a $11.50 price objective for the company.

INMB traded down $0.01 on Friday, reaching $6.14. 26,557 shares of the company’s stock were exchanged, compared to its average volume of 20,817. The company’s 50 day moving average is $7.02 and its 200-day moving average is $8.84. INmune Bio has a twelve month low of $5.06 and a twelve month high of $11.50. The company has a quick ratio of 20.94, a current ratio of 20.94 and a debt-to-equity ratio of 0.01.

In related news, Director Scott Juda purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was purchased at an average cost of $6.00 per share, for a total transaction of $30,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders have purchased 12,000 shares of company stock valued at $72,990. 67.67% of the stock is owned by corporate insiders.

An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc. increased its stake in shares of INmune Bio Inc (NASDAQ:INMB) by 1,556.5% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 3,048 shares of the company’s stock after acquiring an additional 2,864 shares during the period. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.36% of the company’s stock.

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Recommended Story: Why do companies engage in swaps?

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.